1.
Blauvelt A, Rich P, Sofen H, Lambert J, Merola J, Lebwohl M, Hippeli L, Kisa R, Banerjee S, Kimball A. Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo in scalp, nail, and palmoplantar psoriasis: subset analyses of the phase 3 POETYK PSO-1 and PSO-2 trials. J of Skin [Internet]. 2022Jul.7 [cited 2022Aug.10];6(4):s41. Available from: https://jofskin.org/index.php/skin/article/view/1666